Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.
Day 3

EVOLUTION: Comparative study of non-inferiority of two sirolimus eluting stents: One with permanent polymer and the other with degradable polymer.

solaci
solaci
440
0

The EVOLUTION study, (Dr. Junbo Ge, Shanghai Institute, China), compared two sirolimus-eluting stents, one with permanent polymer (Cypher Select, Cordis Corporation, Miami Lakes, Florida, USA) and another with degradable polymer (Excel, JW Medical System Ltd, Weihai, China). A randomized (2:1) was used, open and non-inferiority, including 1923 patients in 30 centers in China (December 2008 to September 2010). The study excluded injured patients with unprotected trunk, rotablator use or previous angioplasty (

The researchers concluded that, until annual follow-up, sirolimus-eluting stent with biodegradable polymer is comparable to sirolimus-eluting stent with permanent polymer. A longer follow-up will be needed to clarify its long-term security.

Ge-EVOLUTION
Junbo Ge
2012-05-17

Previous article
SORT OUT V: Comparison of drug-eluting stents: One with degradable polymer releasing biolimus and the other a permanent polymer sirolimus stent.
Next article
CIBELES: Xience V comparative study vs Cypher for the treatment of total chronic occlusions.
solaci
solaci

More articles by this author

CIBELES: Xience V comparative study vs Cypher for the treatment of total chronic occlusions.

solaci - 0
Spanish-Portuguese multicentre CIBELES study (Raul Moreno, Madrid, Spain) compared two drug-eluting stents - an everolimus (Xience V, Abbott Vascular, USA) and a sirolimus-releasing eluting...

SORT OUT V: Comparison of drug-eluting stents: One with degradable polymer releasing biolimus and the other a permanent polymer sirolimus stent.

solaci - 0
SORT OUT V randomized trial (Odense University Hospital, Denmark) compared Nobori stent, a drug-eluting stent with biodegradable polymer eluting biolimus, versus CYPHER a drug-eluting...

ROMA II RELOAD: Additional charge of statin (rosuvastatin 40 mg or atorvastatin 80 mg within 24 hours of procedure) in patients on whom elective...

solaci - 0
ROMA II RELOAD multicenter study (General Hospital Umberto I, University of Rome, Rome, Italy) assessed the impact of an additional charge of statin in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 3

CIBELES: Xience V comparative study vs Cypher for the treatment of total chronic occlusions.

Spanish-Portuguese multicentre CIBELES study (Raul Moreno, Madrid, Spain) compared two drug-eluting stents - an everolimus (Xience V, Abbott Vascular, USA)...
solaci -
SOLACI Sessionsspot_img

Recent Articles

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Dr. Juan Manuel Pérez - 0
Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

Left Atrial Appendage Closure: Implantation Depth Could Determine Thrombosis Risk

Dr. Andrés Rodríguez - 0
Left atrial appendage closure (LAAC) has undergone significant advances over the past two decades. This progress has been driven by the development of new...

Influence of cusp-overlap and three-cusp coplanar techniques on new-onset conduction disturbances after TAVI

Dr. Juan Manuel Pérez - 0
New-onset conduction disturbances remain one of the most frequent complications after transcatheter aortic valve implantation (TAVI), being associated with worse long-term clinical outcomes. Among...